Você procurou por: stature (Inglês - Maltês)

- treatment of short stature in children with turner syndrome, confirmed by chromosome
- kura ta 'l- istatura qasira fi tfal bis- sindrome ta' turner, ikkonfermata b' analiżi tal- kromosomi.

the majority of the patients presented with short stature, impaired endurance, and musculoskeletal symptoms.
il-maġġoranza tal-pazjenti kellhom statura qasira, reżistenza mnaqqsa u sintomi muskolu-skeletari.

civil society has grown in stature and is more able to fulfil its role as a legitimate partner of local government in developing more inclusive societies.
is-soċjetà ċivili kibret fl-istatura u hi aktar kapaċi taqdi r-rwol tagħha bħala sieħeb leġittimu tal-gvern lokali fl-iżvilupp ta’ soċjetajiet aktar inklużivi.

manufacturing engineers tend to be at the bottom of the pay scale relevant to other engineers, and the profession as a whole has a lower stature.
inġiniera tal-fabbrikazzjoni għandhom tendenza li jkunu fl-aktar skala baxxa tal-pagi meta mqabbla ma' inġiniera oħra, u l-professjoni in ġenerali għandha statura iktar baxxa.

these findings indicate a potential risk for short stature and tooth deformities to infants and children (see section 5.3).
dawn is-sejbiet jindikaw riskju potenzjali ta’ statura qasira u deformità fis-snien għat-trabi u t-tfal (ara sezzjoni 5.3).

slipped capital femoral epiphysis occurs more frequently in case of endocrine disorders and legg-calvé-perthes is more frequent in case of short stature.
slipped capital femoral epiphysis isseħħ b’mod iktar frekwenti f’każ ta’ disturbi endokrinali, u l-marda ta’ legg-calvé-perthes hi iktar frekwenti f’każ ta’ statura qasira.

an open single-arm phase iii study investigating the efficacy and safety of treatment with valtropin in girls with short stature associated with turner syndrome showed a significant effect of study treatment on height velocity.
7 studju open single- arm tal- fażi iii li eżamina l- effikaċja u s- sigurtà ta 'kura b' valtropin fi bniet bi statura qasira assoċjata mas- sindrome ta' turner wera effett sinifikanti tal- kura ttestjata fuq il- veloċità tat- tul.

therefore, at the time of the withdrawal, the chmp’ s view was that that the benefits of nutropinaq in the long-term treatment of children with severe idiopathic short stature did not outweigh its possible risks.
għalhekk, fi żmien l- irtirar, l- opinjoni tas- chmp kienet li l- benefiċċji ta ’ nutropinaq fit- trattament fuq perjodu fit- tul ta ’ tfal bi statura żgħira idjopatika gravi ma kinux jegħlbu r- riskji possibbli tiegħu.

iplex was to be used in children with short stature whose bodies have problems handling growth hormone because: • they have primary insensitivity to the hormone, so that injected growth hormone has no effect. ‘ primary’ means that there is no known reason for the insensitivity. • they are not able to make growth hormone and have received growth hormone in the past, but have developed neutralising antibodies, special proteins than can prevent injected growth hormone from having an effect.
iplex kellu jintuża minn tfal ta ’ statura qasira li ġisimhom ikollu problemi fil- ġestjoni ta ’ l- ormon tat- tkabbir minħabba li: • ikollhom insensittività primarja għall- ormon, u allura jekk jingħataw ormon tat- tkabbir b’ injezzjoni, dan ma jkollu l- ebda effett. ‘ primarja ’ tfisser li ma tkun magħrufa l- ebda raġuni għall- insensittività. • ma jkunux kapaċi jipproduċu ormon tat- tkabbir u jkunu ngħataw ormon tat- tkabbir qabel, iżda jkunu żviluppaw antikorpi newtralizzanti, proteini speċjali li jipprevjenu li l- ormon tat- tkabbir jagħmel effett.